Oncolytic Virotherapy: The Cancer Cell Side

Area of Science:

• Immunology
• Virology
• Oncology
• Molecular Biology

Background:

• Cell autonomous immunity genes are crucial for anti-viral defenses and immune surveillance.
• Tumor immunoediting reduces cancer cell immunostimulatory potential, promoting immune evasion.
• Oncogene-driven metabolism and reduced antiviral defenses favor tumor growth and oncolytic virus selectivity.

Purpose of the Study:

• To review how oncogene-mediated transformation and tumor immunoediting alter the intracellular environment of tumor cells to benefit oncolytic virus replication.
• To explore the link between oncogenic signaling, epigenetic silencing, and immune activation in cancer.

Main Methods:

• Review of existing literature on cell autonomous immunity, tumor immunoediting, oncogenic signaling, and epigenetic regulation.
• Analysis of the interplay between these processes in the context of cancer development and oncolytic virus therapy.

Main Results:

• Oncogene transformation and immunoediting attenuate antiviral defenses, creating a favorable intracellular milieu for oncolytic virus replication.
• Epigenetic silencing is functionally linked to oncogenic signaling, and its restriction can lead to immune activation.
• Oncolytic viruses and epigenetic modifiers represent a therapeutic strategy to activate anti-tumor immunity.

Conclusions:

• The combined effects of oncogenic transformation and immunoediting create vulnerabilities that can be exploited by oncolytic viruses.
• Targeting epigenetic silencing offers a pathway to enhance anti-tumor immune responses.
• Oncolytic viruses and epigenetic modifiers are promising components of novel cancer immunotherapies.